Seguridad de los Fármacos Modificadores de la Enfermedad Biológicos y Dirigidos Sintéticos en Artritis Reumatoide cómo Utilizados en la Práctica Clínica: Resultados del Programa ARTIS
Ann Rheum Dis. 2023;82(5):601–610 doi: 10.1136/ard-2022-223762
Nationwide register-based cohort study corroborates and extends previous evidence that the currently available biologic/targeted synthetic DMARDs have an acceptable and, on the whole, similar safety profile.
Frisell, et al. provide a comprehensive assessment of safety outcomes of particular interest, for most biologic/targeted synthetic DMARDs available for the treatment of RA. They highlight some differences concerning tolerability, specific infection risks, and certain serious, but rare, outcomes, and conclude that these data should be combined with corresponding data on effectiveness to inform risk-benefit trade-offs.
